Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$44.96

-0.33 (-0.73%)

, MRK

Merck

$84.51

1.59 (1.92%)

11:03
09/30/19
09/30
11:03
09/30/19
11:03

AstraZeneca, Merck present detailed results from Phase 3 PROfound trial

AstraZeneca (AZN) and Merck (MRK) presented detailed results from the Phase 3 PROfound trial in 387 men with metastatic castration-resistant prostate cancer, or mCRPC, who have a mutation in their homologous recombination repair genes and whose disease had progressed on prior treatment with new hormonal agent treatments. Results showed a statistically significant and clinically meaningful improvement with LYNPARZA in the primary endpoint of radiographic progression-free survival, or rPFS, improving the time men with BRCA1/2- or ATM-mutated mCRPC lived without disease progression or death to a median of 7.4 months vs. 3.6 months for those treated with abiraterone or enzalutamide. LYNPARZA reduced the risk of disease progression or death by 66% for these men. The trial also met the key secondary endpoint of rPFS in the overall HRRm population, where LYNPARZA reduced the risk of disease progression or death by 51% and improved rPFS to a median of 5.8 months vs. 3.5 months for abiraterone or enzalutamide. The results were presented during the Presidential Symposium at the 2019 European Society of Medical Oncology congress, or ESMO.

AZN

AstraZeneca

$44.96

-0.33 (-0.73%)

MRK

Merck

$84.51

1.59 (1.92%)

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 23

    Oct

  • 29

    Oct

  • 14

    Mar

AZN AstraZeneca
$44.96

-0.33 (-0.73%)

08/13/19
BOFA
08/13/19
DOWNGRADE
Target $7
BOFA
Neutral
Clovis downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill Tazeen Ahmad downgraded Clovis (CLVS) to Neutral and lowered his price target to $7 from $13 after last week's release of positive topline results for its PARP inhibitor Lynparza to treat prostate cancer by the company's competitor AstraZeneca (AZN). The analyst notes that the Lynparza update alters his expectations in the prostate cancer market to assume a two-player landscape from day one, reducing his expectations for Clovis's Rubraca peak sales to $250M from $406M with peak U.S. BRCA penetration of 15%.
08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
09/03/19
DZBN
09/03/19
DOWNGRADE
DZBN
Sell
AstraZeneca downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Elmar Kraus downgraded AstraZeneca to Sell from Hold with a price target of 66 pounds.
09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$84.51

1.59 (1.92%)

08/15/19
LEER
08/15/19
INITIATION
Target $103
LEER
Outperform
Merck initiated with an Outperform at SVB Leerink
SVB Leerink analyst Daina Graybosch initiated Merck with an Outperform rating and $103 price target.
08/16/19
08/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Merck (MRK) initiated with an Outperform at SVB Leerink. 2. DocuSign (DOCU) initiated with a Buy at DA Davidson. 3. iQIYI (IQ) initiated with an Underweight at JPMorgan. 4. Goodyear Tire (GT) initiated with an Outperform at Exane BNP Paribas. 5. BlackBerry (BB) initiated with a Neutral at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/19
RHCO
09/18/19
NO CHANGE
Target $14
RHCO
Hold
Lannett price target raised to $14 from $10 at SunTrust
SunTrust analyst Gregg Gilbert raised his price target on Lannett (LCI) to $14, adjusting his model to reflect its potentially significant opportunity with the recent launch of posaconazole - a generic version of Merck's (MRK) Noxafil. The analyst notes that he now models sales and EBITDA at the higher end of the company's FY20 targets while also raising his FY20 EPS view by 19c to $1.33. Gilbert still keeps his Hold rating on the stock, citing the uncertainty around Lannett's capital structure and limited pipeline visibility as well as the challenging environment for generics.
09/30/19
GUGG
09/30/19
INITIATION
Target $12
GUGG
Buy
Guggenheim starts Bellus Health at Buy with $12 price target
As previously reported, Guggenheim analyst Dana Flanders initiated Bellus Health (BLU) with a Buy rating and $12 price target. BLU-5937 for refractory chronic cough is the primary value driver in "a potential multi-billion dollar category," said Flanders, who also sees the opportunity for label expansion and the potential for M&A interest in Bellus. Merck (MRK) acquired Afferent, which also has a P2X3 antagonist asset called gefapixant, in 2016 for $500M upfront and up to $1.25B with milestones, noted Flanders.

TODAY'S FREE FLY STORIES

GOOGL

Alphabet Class A

$1,306.83

-5.76 (-0.44%)

, GOOG

Alphabet

$1,308.00

-6.71 (-0.51%)

11:45
11/20/19
11/20
11:45
11/20/19
11:45
Periodicals
Some who pre-ordered Google Stadia still can't access service, Kotaku says »

Some customers who…

GOOGL

Alphabet Class A

$1,306.83

-5.76 (-0.44%)

GOOG

Alphabet

$1,308.00

-6.71 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPC

Marathon Petroleum

$61.17

-0.67 (-1.08%)

11:45
11/20/19
11/20
11:45
11/20/19
11:45
Options
Marathon Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
11/20/19
11/20
11:45
11/20/19
11:45
General news
Treasury's $15 B 16-day cash management bill (CMB) stopped at 1.540% »

Treasury's $15 B…

VZ

Verizon

$59.19

-0.31 (-0.52%)

11:39
11/20/19
11/20
11:39
11/20/19
11:39
Hot Stocks
Verizon and Respond unveil third 5G First Responder Lab cohort »

Verizon, in partnership…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 30

    Jan

AMRN

Amarin

$20.18

-2.56 (-11.26%)

, BRY

Berry Petroleum

$7.13

-1.77 (-19.89%)

11:39
11/20/19
11/20
11:39
11/20/19
11:39
On The Fly
Bearish view of Amarin, Berry downgrades among today's top analyst calls »

Check out today's top…

AMRN

Amarin

$20.18

-2.56 (-11.26%)

BRY

Berry Petroleum

$7.13

-1.77 (-19.89%)

TW

Tradeweb Markets

$44.64

1.38 (3.19%)

CBOE

Cboe Global Markets

$121.85

-0.68 (-0.55%)

CGC

Canopy Growth

$17.43

2.11 (13.77%)

I

Intelsat

$7.38

1.3 (21.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 28

    Dec

SYBT

S.Y. Bancorp

$40.66

-0.04 (-0.10%)

11:37
11/20/19
11/20
11:37
11/20/19
11:37
Hot Stocks
S.Y. Bancorp increases quarterly dividend 4% »

Stock Yards Bancorp,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

HUYA

Huya

$21.90

-0.59 (-2.62%)

11:35
11/20/19
11/20
11:35
11/20/19
11:35
Options
HUYA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

UBER

Uber

$28.35

1.32 (4.88%)

11:25
11/20/19
11/20
11:25
11/20/19
11:25
Options
Uber call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

SQ

Square

$67.18

0.75 (1.13%)

, PYPL

PayPal

$104.73

-0.21 (-0.20%)

11:25
11/20/19
11/20
11:25
11/20/19
11:25
Conference/Events
Wedbush payments/IT services analyst to hold an advisor luncheon »

Payments/IT Services…

SQ

Square

$67.18

0.75 (1.13%)

PYPL

PayPal

$104.73

-0.21 (-0.20%)

WP

Worldpay

$0.00

(0.00%)

GPN

Global Payments

$181.54

-0.21 (-0.12%)

TSS

TSYS

$0.00

(0.00%)

FDC

First Data

$0.00

(0.00%)

EVOP

EVO Payments

$27.31

-0.19 (-0.69%)

IIIV

i3 Verticals

$23.04

0.19 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 09

    Dec

  • 10

    Dec

  • 07

    Jan

  • 08

    Jan

  • 26

    Feb

GNPX

Genprex

$0.52

-0.0986 (-15.90%)

11:20
11/20/19
11/20
11:20
11/20/19
11:20
Syndicate
Genprex annoucnes $1.26M registered direct offering »

Genprex announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDC

Teradata

$27.21

0.315 (1.17%)

11:20
11/20/19
11/20
11:20
11/20/19
11:20
Recommendations
Teradata analyst commentary  »

Teradata interim CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/20/19
11/20
11:17
11/20/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$20.18

-0.02 (-0.10%)

11:16
11/20/19
11/20
11:16
11/20/19
11:16
Initiation
Nielsen initiated  »

Nielsen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/20/19
11/20
11:16
11/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$43.50

-0.22 (-0.50%)

11:15
11/20/19
11/20
11:15
11/20/19
11:15
Options
Foot Locker put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

MTZ

MasTec

$66.46

-4.55 (-6.41%)

11:11
11/20/19
11/20
11:11
11/20/19
11:11
Recommendations
MasTec analyst commentary  »

MasTec price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AMZN

Amazon.com

$1,761.95

9.78 (0.56%)

11:09
11/20/19
11/20
11:09
11/20/19
11:09
Hot Stocks
Amazon.com to create 500 jobs at new fulfillment center in Auburndale, Florida »

Amazon announced plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

STZ

Constellation Brands

$185.90

4.93 (2.72%)

11:05
11/20/19
11/20
11:05
11/20/19
11:05
Options
Constellation Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDC

Teradata

$26.93

0.04 (0.15%)

11:05
11/20/19
11/20
11:05
11/20/19
11:05
Hot Stocks
Teradata discloses compensation arrangements granted to interim CEO »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFFI

C&F Financial

$52.65

(0.00%)

11:00
11/20/19
11/20
11:00
11/20/19
11:00
Hot Stocks
C&F Financial raises quarterly dividend 2.7% to 38c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$7.96

-0.57 (-6.68%)

10:55
11/20/19
11/20
10:55
11/20/19
10:55
Options
SunPower put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CRM

Salesforce

$165.46

1.44 (0.88%)

10:55
11/20/19
11/20
10:55
11/20/19
10:55
Conference/Events
Salesforce to host investor day at Dreamforce 2019 »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 16

    Dec

LIVN

LivaNova

$78.56

-0.65 (-0.82%)

10:46
11/20/19
11/20
10:46
11/20/19
10:46
Recommendations
LivaNova analyst commentary  »

LivaNova restructuring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

MO

Altria Group

$47.34

0.4 (0.85%)

10:45
11/20/19
11/20
10:45
11/20/19
10:45
Options
Altria Group call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

10:40
11/20/19
11/20
10:40
11/20/19
10:40
General news
Fed Governor Brainard noted the Fed has taken out insurance »

Fed Governor Brainard…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.